targeted translational rfa for rare tumor subtypes and exceptional responders-revised
TRANSCRIPT
Targeted Translational RFA for Rare Tumor Subtypes and Exceptional Responders
Request for Proposals Deadline: Monday, June 1, 2015, 12 noon Applications are requested for pilot projects that seek to analyze the genomics, transcriptomics, with or without additional ‘omics’ on available human tissue or other cellular material such as circulating tumor cells. Material must be already available, i.e. banked or readily available, i.e. for open or soon to be open protocols that allow access to tissue or blood samples for pilot studies. Rare tumor subtypes includes rare tumors as well as comparative studies of known molecular subtypes within more common tumors. Detailed analysis of molecular subtypes within common tumors is considered responsive. In 2015 there may not be such a thing as a 'common' tumor given all the heterogeneity even within molecular subtypes of common tumors not to mention the intra-‐tumoral heterogeneity. For exceptional responders, common or rare tumors are included, and novel or conventional agents would apply as long as the novelty and significance are clear. The ideal application will state a relevant clinical question of significance to the understanding of the tumor classification, molecular drivers, or mediators of response or resistance. Other questions of interest include analysis of intra-‐ or inter-‐tumor heterogeneity as well as familial associations where cases cluster within families particularly within the FCCC-‐Temple catchment area. A clear delineation of the comparisons to be made along with expected impact of the project in terms of publications, funding, and/or new clinical protocols that take the knowledge to the next level (e.g. proposing patient selection based on molecular features in the context of therapeutic clinical protocols). A goal of the RFA is to encourage interdisciplinary collaboration as well as application of the latest genomic capabilities available including those that are internal to FCCC (targeted sequencing, nanostring, CTC isolation and analysis strategies). Applications may introduce novel directions to existing open or closed clinical studies where human samples with clinical outcomes are available. Available Support: Funds available will support actual use of technology and any costs associated with sample identification or analysis. Funds for this RFA may not be used for salary support. The typical award will be in the range of 25-‐50K and will be judged on expected return-‐on-‐investment (ROI) for a given request and scope of work that can have impact. 5-‐6 awards are expected to be made. Application Deadline: June 1, 2015 at 12:00 pm. Eligible Principal Investigators must be a member of one of the five CCSG Research Programs of the Fox Chase Cancer Center.
Submission Guidelines: Applications need an abstract, significance, preliminary information, hypothesis, goals/specific aim/subaims, feasibility and expected impact as described above. Applications must not exceed five (5) pages, including the above sections and research design, but excluding references. In addition provide a detailed budget page (direct costs only, no salary support or indirect costs allowed) and an NIH Biosketch for the PI, co-‐PI(s) and Collaborators that includes Other Support information. Proposals should include a title page with the proposal title, PI, Co-‐PI(s) (if applicable), and Collaborators. Review Process Applications will be reviewed by the end of June with awards becoming available for use by July 2015. Please direct any questions to Wafik El-‐Deiry ([email protected]).